Trials / Completed
CompletedNCT02678793
A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)
An Open-Label, Multiple-Dose Extension Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Centrexion Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Subjects who have completed study 4975-MN-202 will be eligible to receive open-label treatment with CNTX-4975 200 µg in study 4975-MN-203 if they meet the inclusion/exclusion criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CNTX-4975 |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2016-12-01
- Completion
- 2017-03-01
- First posted
- 2016-02-10
- Last updated
- 2018-05-09
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02678793. Inclusion in this directory is not an endorsement.